Efficacy of Galantamine to Treat Schizophrenia

Phase 4 Terminated 21 enrolled Seattle Institute for Biomedical and Clinical Research

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements from baseline to end of study on a measure of quality of life and a measure of independent living skills.

Timeline

Start: 2005-02
Primary completion: 2007-06
Completion: 2007-06

Outcome

Outcome not reported

Stopped: “Study terminated due to no apparent benefit.”

Publications

Background Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry. 2002 Jul;159(7):1244-5. doi: 10.1176/appi.ajp.159.7.1244. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galantamine	Small molecule	12 mg	—